Astria Therapeutics Stock Skyrockets 53% After $700M Buyout – What’s Next?
On Oct. 14, 2025, Astria was swept into the headlines by a surprise $700+ million takeover. BioCryst Pharmaceuticals announced a definitive merger agreement to acquire Astria for $8.55 in cash plus 0.59 shares of BioCryst stock per Astria share marketscreener.com reuters.com. This values Astria at roughly $920M equity and $700M enterprise stocktitan.net. The Boards of both companies approved the deal, which is expected to close in Q1 2026 stocktitan.net. Astria CEO Jill Milne will join BioCryst’s board post-merger stocktitan.net. Market reaction: News of the deal caused Astria’s stock to jump sharply. Reuters reported ATXS shares rose over 40% in pre-market trading on Oct. 14 reuters.com, and ChartMill noted a 44.27% pre-market gain to $12.22 chartmill.com. On Oct. 13 close ATXS was $8.47 investing.com; as of Oct. 14 morning it was about $11.90 investing.com. Trading in ATXS was briefly halted on Oct. 14 due to pending news marketbeat.com.
